Current Edition


GlaxoSmithKline’s HIV drug Cabenuva scores FDA nod for 2-month dosing

Last January, when GlaxoSmithKline’s ViiV Healthcare won a long-awaited approval for its long-acting HIV treatment Cabenuva, it was hailed as a game-changer as it removed …

Continue Reading →

Johnson & Johnson CEO: Consumer health split won’t interfere with our ‘more aggressive’ approach to M&A

For anyone playing a drinking game, taking a sip each time the phrase “the new Johnson & Johnson,” was uttered during the company’s fourth-quarter earnings …

Continue Reading →

Verana Health lands J&J, Novo backing in $150M round to fund real-world database for drug, device development

With a new CEO at the helm, the recent launch of an artificial-intelligence-powered data analytics engine and, now, the close of its largest funding round …

Continue Reading →
Alex Gorsky

Amid consumer spinoff and CEO transition, Johnson & Johnson names new leadership team

Less than a month after revealing a plan to spin its consumer health business off as a new publicly traded company, Johnson & Johnson has …

Continue Reading →

Aspen closes in on Africa license for Johnson & Johnson’s COVID-19 vaccine

One of Johnson & Johnson’s long-held pandemic manufacturing partners just made headway in its quest to license the company’s shot in Africa. Aspen Pharmacare on …

Continue Reading →

Novartis may have a buyer for $21B generics unit Sandoz

Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from …

Continue Reading →

J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win

Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …

Continue Reading →

Amid a push to resolve opioid and talc claims, Johnson & Johnson settles Risperdal litigation for $800M

Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its …

Continue Reading →

Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’

Over the last year, the Johnson & Johnson COVID-19 vaccine has been commonly referred to as a single-shot alternative to the two-dose regimens of mRNA …

Continue Reading →

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer to …

Continue Reading →